Key statistics dashboard for ALX Oncology Holdings Inc. (ALXO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Stock Data
| Price | $1.76 |
| Market Cap | $237M |
| Beta | 0.50 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.67 |
| Price / Book | 1.88 |
| P/S | 0.00 |
| P/FCF | -3.58 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 9.71 |
| Quick Ratio | 9.71 |
| Cash Ratio | 1.54 |
| Debt / Equity | 0.07 |
| Debt / Assets | 6.03% |
| Interest Coverage | -58.67 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -21.32 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.00 |
| Cash per share | 1.02 |
| FCF per share | -0.52 |
| Tangible Book Value per share | 1.00 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 0.86 |
Related companies: ANNX · BCYC · GLUE · KYMR · NKTX · STOK · TNYA
Explore sector: Healthcare · Biotechnology
More sections of ALXO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks